Mesa Laboratories (MLAB) AI Stock Analysis

• Market Cap: $392.75M
• Dividend Yield: 0.86%
• Average Volume (3M): 198.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: 11.47%
• EPS Growth: 99.25%
• Country: US
• Employees: 736
• Sector: Technology
• Sector Strength: 91
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 2.25
• Shares Outstanding: 5,501,454
• 10 Day Avg. Volume: 166,953
• 30 Day Avg. Volume: 198,452
• PEG Ratio: -2.11
• Price to Book (P/B): 2.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 10.12
• Enterprise Value/Market Cap: 1.47
• Enterprise Value/Revenue: 0.62
• Enterprise Value/Gross Profit: 3.92
• Enterprise Value/Ebitda: -0.88
• 1Y Price Target: $100.00
• Price Target Upside: 40.08% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: $68.00 ▼(-4.75%Downside)

The overall stock score for Mesa Laboratories is 45, driven primarily by its financial performance and technical analysis. Despite strong revenue growth and cash flow generation, the company's profitability challenges and negative valuation metrics significantly impact its attractiveness. Technical indicators further highlight the stock's current bearish trend, contributing to a cautious outlook.

Mesa Laboratories Business Overview & Revenue Model

Company Description

Mesa Laboratories, Inc. (MLAB) is a diversified technology company that focuses on designing, manufacturing, and marketing quality control instruments and consumables. The company's operations are spread across several sectors, including healthcare, pharmaceuticals, food and beverage, industrial, and environmental. Mesa Labs' core products and services include data loggers, medical meters, calibration solutions, and biological indicators, which are vital for ensuring the precision and safety of various processes in its target industries.

How the Company Makes Money

Mesa Laboratories generates revenue through the sale of its specialized products and services across its multiple business divisions. Key revenue streams include the sales of instruments and consumables, such as biological indicators and calibration solutions, which are critical for quality control and compliance in the industries it serves. Additionally, the company offers calibration and maintenance services that provide ongoing revenue. Mesa Labs benefits from long-term relationships with clients, often secured through service contracts and recurring sales of consumables. Strategic acquisitions and partnerships also play a role in expanding its product offerings and market reach, thus contributing to its earnings.

Mesa Laboratories Financial Statement Overview

Summary

Mesa Laboratories shows resilience in revenue growth and cash flow generation, but profitability remains a concern with recurring net losses. The balance sheet indicates moderate leverage, and the company maintains positive free cash flow. Addressing profitability and maintaining financial discipline will be key to improving overall financial health.

Income Statement

The income statement reflects mixed performance. While there is a strong revenue growth from the previous year, margins remain under pressure. The gross profit margin improved to 62.6%, but the net profit margin is negative due to a net loss. EBITDA margin slightly improved to 17.6%, indicating some operational efficiency. However, the company needs to address ongoing profitability challenges.

Balance Sheet

The balance sheet shows moderate financial health with a debt-to-equity ratio of 1.14, indicating moderate leverage. The equity ratio stands at 36.9%, suggesting a balanced asset financing structure. Return on equity is negative due to the net loss, but equity remains substantial. Continuous monitoring of debt levels is advisable to prevent financial strain.

Cash Flow

The cash flow statement demonstrates strong free cash flow generation, with a growth rate of 1.8%. The operating cash flow to net income ratio is not applicable due to the net loss, but cash flow performance is robust, indicating operational cash generation capability. Positive cash flow metrics highlight financial flexibility despite profitability issues.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	240.98M	216.19M	219.08M	184.34M	133.94M
Gross Profit	150.87M	133.25M	133.69M	109.09M	87.01M
EBITDA	42.35M	-238.38M	36.45M	29.77M	12.36M
Net Income	-1.97M	-254.25M	930.00K	1.87M	3.27M
Balance Sheet
Total Assets	433.35M	446.80M	661.83M	707.37M	600.15M
Cash, Cash Equivalents and Short-Term Investments	27.32M	28.21M	32.91M	49.35M	263.87M
Total Debt	181.47M	231.30M	170.27M	221.13M	146.70M
Total Liabilities	273.52M	301.40M	268.35M	313.57M	193.92M
Stockholders Equity	159.83M	145.39M	393.48M	393.80M	406.23M
Cash Flow
Free Cash Flow	42.31M	41.57M	23.44M	34.79M	35.08M
Operating Cash Flow	46.81M	44.13M	27.98M	39.22M	37.07M
Investing Cash Flow	-4.50M	-81.31M	-9.49M	-305.23M	-1.99M
Financing Cash Flow	-44.51M	32.84M	-33.33M	52.58M	146.23M

Mesa Laboratories Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 71.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLAB, the sentiment is Negative. The current price of 71.39 is below the 20-day moving average (MA) of 87.00, below the 50-day MA of 98.61, and below the 200-day MA of 119.38, indicating a bearish trend. The MACD of -7.94 indicates Positive momentum. The RSI at 33.82 is Neutral, neither overbought nor oversold. The STOCH value of 14.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLAB.

Mesa Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYTS	75 Outperform	$543.08M	25.33	10.42%	1.10%	17.89%	-23.37%
BELFA	73 Outperform	$1.33B	26.98	11.87%	0.25%	-6.15%	-42.24%
DAKT	69 Neutral	$781.88M	32.01	-3.96%	―	-7.53%	-126.35%
VPG	69 Neutral	$379.29M	125.04	0.94%	―	-14.26%	-87.37%
Sector *	63 Neutral	$34.55B	5.25	-11.40%	1.91%	5.47%	-20.39%
FARO	56 Neutral	$849.75M	―	-0.34%	―	-4.76%	97.93%
MLAB	45 Neutral	$392.75M	―	-1.29%	0.86%	11.47%	99.25%